Related Experiment Video
Updated: Jun 27, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Long-term outcome after drug eluting stenting in patients with ST-segment elevation myocardial infarction: data from
Gianluca Campo1, Francesco Saia, Gianfranco Percoco
1Unità Operativa di Cardiologia, Azienda Ospedaliera Universitaria S. Anna, Ferrara, Italy. cmpglc@unife.it
Insights
Drug-eluting stents (DES) show reduced target vessel revascularization and major adverse cardiac events in the first two years post-STEMI PCI. Long-term safety and efficacy require further investigation.
Area of Science:
- Cardiology
- Interventional Cardiology
- Biomaterials
Background:
- Long-term outcomes of drug-eluting stents (DES) in primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) remain unclear.
- Comparison of DES versus bare metal stents (BMS) in STEMI patients is crucial for clinical decision-making.
Purpose of the Study:
- To compare the long-term safety and efficacy of DES versus BMS implantation in patients with STEMI undergoing primary PCI.
Main Methods:
- Analysis of 4764 patients, with 706 (15%) receiving DES.
- Assessment of cumulative incidence of major adverse cardiac events (MACE) and stent thrombosis (ST).
Main Results:
- DES implantation significantly reduced target vessel revascularization (TVR) and major adverse cardiac events (MACE) within the first two years.
- No significant difference in death or reinfarction rates; stent thrombosis rates were similar between DES and BMS.
- A trend towards increased adverse events in the third year was observed with DES.
Conclusions:
- DES implantation in primary PCI for STEMI is safe and effective in reducing TVR and MACE in the initial two years.
- Further long-term follow-up data are necessary to fully ascertain the safety and efficacy of DES in STEMI patients.
Background:
The long-term safety and efficacy of drug eluting stents (DES) implanted during primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) is unclear. The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES vs. bare metal stent (BMS) implantation.
Methods:
In the present analysis 4764 patients were enrolled (706, 15%, received DES). We assessed the cumulative incidence of major adverse cardiac events (MACE) and stent thrombosis (ST).
Results:
Overall, no significant difference emerged for the rates of death and reinfarction. DES implantation was associated to a reduction of target vessel revascularization (TVR) (HR 0.65, 95%CI 0.47-0.91; p=0.01), leading to a MACE reduction (HR 0.7, 95%CI 0.56-0.86; p<0.01). In particular, during the first 2 years we observed less adverse events in the DES group, mainly because of a lower TVR rate (TVR: HR 0.56, 95%CI 0.37-0.83, p<0.01; MACE: HR 0.71, 95%CI 0.54-0.94, p=0.01). On the contrary, during the third year, adverse events tended to be higher in the DES group. ST did not differ between DES and BMS groups (p=0.6). No differences were observed between sirolimus eluting stents and paclitaxel eluting stents.
Conclusions:
DES implantation during primary PCI is safe and associated with a significant TVR and MACE reduction in the first two years, whereas a trend to have more adverse events in the third year is observed. More data about long-term follow-up are needed to better evaluate both safety and efficacy of DES in the setting of STEMI.
